ACE and cardiomyopathy: Regarding cardioprotective therapy, there were a number of preclinical trials using animal models which reported equivalent preventive effects of angiotensin-converting enzyme inhibitors (ACEis), angiotensin II receptor blockers (ARBs) or statins [61] against doxorubicin-induced cardiomyopathy.